TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma.

Maximilian O SchaettlerRupen DesaiAnthony Z WangAlexandra J LivingstoneDale K KobayashiAndrew T CoxonJay A Bowman-KiriginConnor J LiuMao LiDiane E BenderMichael J WhiteDavid M KranzTanner M JohannsGavin P Dunn

Published in: Journal for immunotherapy of cancer (2023)

We generated and characterized the first TCR transgenic against an endogenous neoantigen within a preclinical glioma model and demonstrated the therapeutic potential of adoptively transferred neoantigen-specific T cells. The MISTIC mouse provides a powerful novel platform for basic and translational studies of antitumor T-cell responses in glioblastoma.

Keyphrases

cell therapy
regulatory t cells
stem cells
mesenchymal stem cells
high throughput
case control
bone marrow
optic nerve